Trial · NCT03263091
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
OL and OL High-EPO Components: Number of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) ≥8 Weeks (≥56 Consecutive Days) Since First Dose in the First 28 Weeks of Treatment | OL Component (Cohort 1): Roxadustat 1.5 mg/kg | 3 | Participants | ||
OL and OL High-EPO Components: Number of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) ≥8 Weeks (≥56 Consecutive Days) Since First Dose in the First 28 Weeks of Treatment | OL Component (Cohort 2): Roxadustat 2.0 mg/kg | 1 | Participants | ||
OL and OL High-EPO Components: Number of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) ≥8 Weeks (≥56 Consecutive Days) Since First Dose in the First 28 Weeks of Treatment | OL Component (Cohort 3): Roxadustat 2.5 mg/kg | 5 | Participants | ||
OL and OL High-EPO Components: Number of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) ≥8 Weeks (≥56 Consecutive Days) Since First Dose in the First 28 Weeks of Treatment | OL High-EPO Component: Roxadustat 2.5 mg/kg | 3 | Participants | ||
| DB Component: Number of Participants Who Achieved RBC TI ≥56 Consecutive Days Since First Dose in the First 28 Weeks of Treatment | DB Component: Roxadustat | 38 | Participants | ||
| DB Component: Number of Participants Who Achieved RBC TI ≥56 Consecutive Days Since First Dose in the First 28 Weeks of Treatment | DB Component: Placebo | 19 | Participants | ||
| OL and OL High-EPO Components: Number of Participants Who Achieved TI ≥50% Reduction From Baseline in Number of Packs of Red Blood Cells (pRBC) Transfusions Over 8 Weeks | OL Component (Cohort 1): Roxadustat 1.5 mg/kg | 5 | Participants | ||
| OL and OL High-EPO Components: Number of Participants Who Achieved TI ≥50% Reduction From Baseline in Number of Packs of Red Blood Cells (pRBC) Transfusions Over 8 Weeks | OL Component (Cohort 2): Roxadustat 2.0 mg/kg | 3 | Participants | ||
| OL and OL High-EPO Components: Number of Participants Who Achieved TI ≥50% Reduction From Baseline in Number of Packs of Red Blood Cells (pRBC) Transfusions Over 8 Weeks | OL Component (Cohort 3): Roxadustat 2.5 mg/kg | 7 | Participants | ||
| OL and OL High-EPO Components: Number of Participants Who Achieved TI ≥50% Reduction From Baseline in Number of Packs of Red Blood Cells (pRBC) Transfusions Over 8 Weeks | OL High-EPO Component: Roxadustat 2.5 mg/kg | 8 | Participants | ||
| DB Component: Number of Participants Who Achieved TI ≥56 Consecutive Days Since First Dose in 52 Weeks of Treatment | DB Component: Roxadustat | 44 | Participants | ||
| DB Component: Number of Participants Who Achieved TI ≥56 Consecutive Days Since First Dose in 52 Weeks of Treatment | DB Component: Placebo | 23 | Participants | ||
| DB Component: Number of Participants Who Achieved TI ≥56 Consecutive Days Anytime During the Study | DB Component: Roxadustat | 52 | Participants | ||
| DB Component: Number of Participants Who Achieved TI ≥56 Consecutive Days Anytime During the Study | DB Component: Placebo | 29 | Participants | ||
| DB Component: Number of Participants Who Achieved ≥50% Reduction From Baseline in Number of pRBC Transfusions Over 8 Weeks | DB Component: Roxadustat | 59 | Participants | ||
| DB Component: Number of Participants Who Achieved ≥50% Reduction From Baseline in Number of pRBC Transfusions Over 8 Weeks | DB Component: Placebo | 37 | Participants | ||
| DB Component: Cumulative Number of Participant Exposure Weeks (PEW) of TI Over the First 28 Weeks of Treatment | DB Component: Roxadustat | 9.60 | Standard Deviation 11.537 | weeks | |
| DB Component: Cumulative Number of Participant Exposure Weeks (PEW) of TI Over the First 28 Weeks of Treatment | DB Component: Placebo | 7.60 | Standard Deviation 11.557 | weeks | |
| DB Component: Change From Baseline in Number of pRBC Packs Transfused Over the First 28 Weeks of Treatment | DB Component: Roxadustat | -0.13 | Standard Deviation 2.314 | pRBC packs | |
| DB Component: Change From Baseline in Number of pRBC Packs Transfused Over the First 28 Weeks of Treatment | DB Component: Placebo | 0.44 | Standard Deviation 1.833 | pRBC packs |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03263091/results